MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the year ending 2025-12-31.

Cash Flow Overview

Free Cash flow
-$1,997K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Accrued expenses and other liabi...
    • Proceeds from issuance of aditxt...
    • Noncash interest expense
    • Others
Negative Cash Flow Breakdown
    • Gain on accounts payable and acc...
    • Trade accounts receivable
    • Gain on change in accounting est...
    • Others

Cash Flow
2025-12-31
Net income (loss)
391
Gain on change in accounting estimates on contingent royalty liability
1,933
Change in fair value of financial instruments
-359
Inventory write-down for excess & obsolescence and loss on purchase commitment
1,012
Loss on contingent liability
54
Stock-based compensation
166
Depreciation
19
Amortization of intangible asset
499
Noncash interest expense
2,366
Noncash right-of-use asset amortization
108
Net loss on disposal or impairment of property and equipment
-20
Gain on accounts payable and accrued expenses settlements
5,636
Trade accounts receivable
2,648
Inventories
260
Prepaid and other assets
-356
Accounts payable
182
Accrued expenses and other liabilities
4,468
Accrued compensation
-907
Contingent liabilities
-499
Operating lease liabilities
-109
Net restricted cash and cash equivalents used in operating activities
-1,992
Payments related to intangible asset acquisition
57
Purchases of property and equipment
5
Net restricted cash and cash equivalents used in investing activities
-62
Borrowings under short-term debt
383
Proceeds from issuance of aditxt notes related party
2,425
Payments under short-term debt and notes carried at fair value
905
Cash paid for financing costs
12
Net restricted cash and cash equivalents provided by financing activities
1,891
Net change in restricted cash and cash equivalents
-163
Restricted cash and cash equivalents, beginning of period
741
Restricted cash and cash equivalents, end of period
578
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofaditxt notes related...$2,425K Borrowings undershort-term debt$383K Net restricted cashand cash...$1,891K Canceled cashflow$917K Net change inrestricted cash and cash...-$163K Canceled cashflow$1,891K Accrued expenses andother liabilities$4,468K Noncash interestexpense$2,366K Inventory write-down forexcess & obsolescence...$1,012K Amortization of intangibleasset$499K Net income (loss)$391K Change in fair value offinancial instruments-$359K Prepaid and other assets-$356K Accounts payable$182K Stock-based compensation$166K Noncash right-of-useasset amortization$108K Loss on contingentliability$54K Net loss on disposalor impairment of...-$20K Depreciation$19K Payments undershort-term debt and notes ...$905K Cash paid forfinancing costs$12K Net restricted cashand cash...-$1,992K Canceled cashflow$10,000K Net restricted cashand cash...-$62K Gain on accountspayable and accrued...$5,636K Trade accountsreceivable$2,648K Gain on change inaccounting estimates on...$1,933K Accrued compensation-$907K Contingent liabilities-$499K Inventories$260K Operating leaseliabilities-$109K Payments related tointangible asset...$57K Purchases of property andequipment$5K

Evofem Biosciences, Inc. (EVFM)

Evofem Biosciences, Inc. (EVFM)